The pharmaceutical lobby strongly opposed the Biden administration’s plan to directly negotiate drug prices for 10 medications with Medicare. PhRMA argued this will hurt innovation, but advocates note that drug companies make 76% more than needed for R&D. Eliquis, which costs Medicare over $16 billion, will be subject to negotiations. The policy was enabled by the Inflation Reduction Act, which PhRMA spent millions lobbying against. PhRMA sued over the negotiations, but the DOJ moved to dismiss the case. Advocates believe this defeat of Big Pharma will not be the last as negotiations may expand to over 100 drugs in the future, greatly helping seniors and people with disabilities access affordable medications.

  • circularfish@beehaw.orgM
    link
    fedilink
    arrow-up
    46
    ·
    edit-2
    1 year ago

    Amazed at how the same people who defend a business model that depends on price inelasticities to extract the last dime for lifesaving meds somehow react with horror at the idea that the biggest negotiator of pharmaceutical prices in the U.S. has the gall to negotiate lower prices. The government isn’t ‘dictating’ anything. It is using its market power to drive the price down.

    That is the vaunted free market at work. Anything else is just corporate socialism.

      • circularfish@beehaw.orgM
        link
        fedilink
        arrow-up
        15
        ·
        1 year ago

        That was a dig directed at those that shout “socialism “ at things that are clearly not socialism (like negotiating prescription drug prices), but you are of course correct. Thank you for correcting my rhetorical excess, internet friend!